Starting interferon-beta-1a (Rebif New Formulation) immediately upon an episode of a clinically isolated syndrome delayed progression to full-blown multiple sclerosis, but once-weekly treatment was less effective than the standard dosing interval, a researcher said here.
A randomized, placebo-controlled trial called REFLEX showed that 62% and 76% of patients assigned to 44 mcg of interferon subcutaneously three times or once weekly, respectively, met 2005 McDonald criteria for MS after two years -- the study's primary endpoint -- compared with 86% of patients treated with placebo, said Mark Freedman, MD, of the University of Ottawa.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1765